"Cannabis and Migrains"

A migraine is a primary headache disorder characterized by recurrent headaches that are moderate to severe.

Typically, the headaches affect one half of the head, are pulsating in nature, and last from a few hours to 3 days.

Associated symptoms may include nausea,vomiting & sensitivity to light,sound or smell.

A surprising fact is that cannabis and tinctures have been used to treat headaches and migraines for hundreds and possibly even thousands of years.

Some of the prevailing theories about how cannabis can help with migraines and headaches have to do with its potent and proven properties as an analgesic (pain reliever), and antiemetic (preventing nausea and vomiting), and due to its powerful anti-inflammatory effects.

The good news is that studies centering around the effects on headaches and migraines have shown a lot of promise and it may be just the solution you’ve been searching for.

"CBD and Schizophrenia Safety and Effectiveness"

Schizophrenia is a mental illness characterized by continuous or relapsing episodes of psychosis.

Major symptoms include hallucinations, delusions and disorganized thinking. Other symptoms include social withdrawal, decreased emotional expression, and lack of motivation.

Cannabis and mental health are strongly linked.Cannabis helps support health across various facets of mind, brain and body. But there is no end to the wellness advantages it can offer.Cannabis can assist with mental health, help clear your mind, and alleviate depression.It will help you concentrate, and open up a whole fresh realm of energy and liveliness.

The two most abundant cannabinoids in Cannabis are THC and CBD. Different forms of cannabis vary in the relative proportions of THC and CBD, and the risk of psychotic symptoms and impaired cognitive functioning following cannabis use is lower with cannabis preparations that have a relatively high CBD content.

The aim of the present study was to explore the safety and effectiveness of CBD as an adjunctive treatment in schizophrenia. Researchers examined the effects of CBD on positive and negative psychotic symptoms, cognitive performance, level of functioning, and the treating psychiatrist’s overall clinical impression.

"Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy"

There has been a dramatic increase in the number of children diagnosed with autism spectrum disorders (ASD) worldwide. 

Recently anecdotal evidence of possible therapeutic effects of cannabis products has emerged. 

The aim of this study is to characterize the epidemiology of ASD patients receiving medical cannabis treatment and to describe its safety and efficacy. 

Researchers analyse the data prospectively collected as part of the treatment program of 188 ASD patients treated with medical cannabis between 2015 and 2017. The treatment in majority of the patients was based on cannabis oil containing 30% CBD and 1.5% THC.

The Study...

During the study period, 188 ASD patients initiated the treatment. Diagnosis of ASD was established in accordance with the accepted practice in Israel. 6 board certified paediatric psychiatrists and neurologists were responsible for treatment of 125 patients (80.6%), the remaining 30 children were referred by 22 other physicians.

"CBD Vs COVID-19"

In a previeus article we had speak about cannabis terpens against Covid-19. Now we examine the first study of that article to understand better, not only, the way CBD can help us with viruses but how CBD act with our bodies for a better health.Lets say that this is another litle pice of the puzzle...

Researchers at the University of Lethbridge say while clinical trials still need to be done, data they’ve been collecting over the past four years shows promise that some cannabis extracts may help in the prevention and treatment of COVID-19.

The researchers of this study, Olga and Igor Kovalchuk have been working with cannabis since 2015, using varieties from around the world to create new hybrids and develop extracts that demonstrate certain therapeutic properties.

"When COVID-19 started, Olga had the idea to revisit our data, and see if we can utilize it for COVID.We were totally stunned at first, and then we were really happy," says Olga.

"It was like a joker card, you know, coronavirus. It just mixes up everybody’s plans," says Olga.

"EIHA approve plan for CBD & THC studies"

The main hemp industry body in Europe has received a green light from its members to move forward with “unprecedented” studies on cannabidiol and THC as part of a joint novel food authorization application.

An “overwhelming majority” of European Industrial Hemp Association members voted on Monday in favor of “the principles of the special contribution structure” for the group’s joint application for novel food authorization.

EIHA members agreed last year to submit a joint novel foods application with “a range of CBD extracts” to UK and EU authorities, and the association revealed the anticipated scope and costs associated with the joint application last month.

The anticipated cost of the joint application project is going up. EIHA projected that around €3.5 million ($3.9 million) will be invested over the next two to three years in “unprecedented studies” on the toxicology of CBD and THC.

The EIHA previously estimated the cost for the lab analysis of CBD and THC at €1.8 million ($2 million).